Home
About
News
Join Us
Contact

Newsroom

For press inquiries, please contact Amy Cook
email: amy@magnusmed.com
phone: 925.200.2125

Featured On

Contact Us

	1350 Old Bayshore Highway Suite 600 Burlingame CA 94010 USA
	(415) 231-7407
	info@magnusmed.com

News

Latest News And Press Releases

Magnus Medical Receives FDA Clearance for the SAINT Neuromodulation System for Non-Invasive, Individualized and Precise Treatment of Severe Depression

Devices for Depression Aim for a Network Effect

Join Us

We Are Hiring.

We are looking for individuals who are personally and boldly committed to improving treatment for mental health.

View open positions HERE

We Are Social

Rx Only
The SAINT® Neuromodulation System is indicated for the treatment of Major Depressive Disorder (MDD) in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. The SAINT Neuromodulation System is contraindicated for: patients with non-removable conductive, ferromagnetic, or other magnetic-sensitive metal anywhere in the head or within 30cm of the stimulation coil; patients who have an active or inactive implanted device; or patients with increased intracranial pressure or intracardiac lines, intravenous pumps, or dose calculators. Consult product labeling for a complete list of contraindications, warnings, and precautions. Side effects including headache, fatigue, anxiety, and treatment-site discomfort were shown in clinical trials. Risks associated with transcranial magnetic stimulation, including seizure and worsening depression or suicidality, may exist. Results may vary.

Financial Conflict of Interest Policy

© 2023 Magnus Medical and The Board of Trustees of the Leland Stanford Junior University. MAGNUS MEDICAL and the MAGNUS MEDICAL Logo are the trademarks of Magnus Medical, Inc. SAINT and the SAINT Logo are used under license from Stanford University.